Oral agent shows durable improvement in SUI patients

November 1, 2004

San Diego-Treatment with the dual neurotransmitter reuptake inhibitor duloxetine (Yentreve) results in durable improvement in symptoms of stress urinary incontinence, according to a study of open-label transition from placebo to active therapy.

Related Content:

Drug Therapy | Female Urology | News